Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVONORGESTREL AND ETHINYL ESTRADIOL vs DELESTROGEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Levonorgestrel is a progestin that suppresses gonadotropin release, inhibiting ovulation; ethinyl estradiol is an estrogen that stabilizes the endometrium and provides feedback inhibition on the hypothalamic-pituitary-ovarian axis, preventing follicular development and ovulation.
Estradiol, the active component, binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene transcription and exerting estrogenic effects on the reproductive, cardiovascular, skeletal, and central nervous systems.
Prevention of pregnancy in women who elect to use oral contraceptives,Treatment of moderate acne vulgaris in women at least 15 years old, after topical therapy failure, who have achieved menarche,Oral contraception for women with hypermenorrhea or dysmenorrhea (off-label),Emergency contraception (off-label)
Moderate to severe vasomotor symptoms due to menopause,Moderate to severe symptoms of vulvar and vaginal atrophy due to menopause,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prostate cancer (palliative therapy),Breast cancer (palliative therapy in selected cases),Prevention of postmenopausal osteoporosis (off-label)
Oral, 1 tablet daily containing 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol, or 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol, taken at the same time each day for 21 days followed by 7 placebo tablets, or continuous daily dosing as per product labeling.
10-20 mg intramuscularly every 4 weeks for estrogen replacement therapy.
Levonorgestrel: terminal half-life approximately 24-32 hours. Ethinyl estradiol: terminal half-life approximately 13-27 hours (mean ~17 hours). The half-lives are relevant for once-daily dosing, achieving steady state within 5-7 days.
Terminal elimination half-life: ~12-24 hours; clinical context: prolonged with hepatic impairment, steady-state achieved within ~5-7 days of daily IM dosing
No dose adjustment required for mild to moderate renal impairment (GFR >=30 m L/min). For severe renal impairment (GFR <30 m L/min) or end-stage renal disease, use is not recommended due to potential accumulation of ethinyl estradiol and lack of safety data.
No specific dose adjustment recommended; use with caution in severe renal impairment due to potential fluid retention.
Cigarette smoking increases the risk of serious cardiovascular events from combined oral contraceptive use. This risk increases with age, especially in women over 35, and with the number of cigarettes smoked. Women who use combined oral contraceptives should be strongly advised not to smoke.
First trimester: Exposure associated with minor malformations (cardiac defects, limb reduction) in some studies, but absolute risk low. Second/third trimester: Androgenic effects (clitoromegaly, labial fusion) in female fetuses; no major structural anomalies attributed. Avoid use during pregnancy.
Delestrogen (estradiol valerate) is contraindicated in pregnancy. First trimester: associated with increased risk of congenital anomalies including cardiovascular and limb defects. Second and third trimesters: risk of urogenital abnormalities in female fetuses, vaginal adenosis, and cervical dysplasia. Fetal exposure may lead to reproductive tract abnormalities and increased lifetime cancer risk.
1) Counsel patients that missing pills increases risk of breakthrough bleeding and pregnancy; strict adherence is critical. 2) Consider potential for reduced efficacy with certain anticonvulsants (e.g., carbamazepine, phenytoin) and antibiotics (e.g., rifampin). 3) Not recommended in patients with BMI >35 due to increased failure risk. 4) Monitor blood pressure at follow-up; estrogen component may raise BP. 5) Advise that spotting/breakthrough bleeding is common in first 3 months; if persistent, consider alternative formulations or etiologies.
Delestrogen (estradiol valerate) is an oil-based IM injection; ensure deep intramuscular administration into the gluteal muscle and avoid intravascular injection. Rotate injection sites to prevent lipodystrophy. Monitor for thrombophlebitis, hypertension, and glucose intolerance. Use with caution in patients with estrogen-dependent tumors or history of thromboembolism.
No interactions on record
No interactions on record
Common clinical questions about LEVONORGESTREL AND ETHINYL ESTRADIOL vs DELESTROGEN, answered by our medical review team.
LEVONORGESTREL AND ETHINYL ESTRADIOL is a Estrogen that works by Levonorgestrel is a progestin that suppresses gonadotropin release, inhibiting ovulation; ethinyl estradiol is an estrogen that stabilizes the endometrium and provides feedback inhibition on the hypothalamic-pituitary-ovarian axis, preventing follicular development and ovulation.. DELESTROGEN is a Estrogen that works by Estradiol, the active component, binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene transcription and exerting estrogenic effects on the reproductive, cardiovascular, skeletal, and central nervous systems.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVONORGESTREL AND ETHINYL ESTRADIOL and DELESTROGEN depend on the specific clinical indication. These are both Estrogen agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVONORGESTREL AND ETHINYL ESTRADIOL is: Oral, 1 tablet daily containing 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol, or 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol, taken at the same time each day for 21 days followed by 7 placebo tablets, or continuous daily dosing as per product labeling.. The standard adult dose of DELESTROGEN is: 10-20 mg intramuscularly every 4 weeks for estrogen replacement therapy.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVONORGESTREL AND ETHINYL ESTRADIOL and DELESTROGEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVONORGESTREL AND ETHINYL ESTRADIOL is classified as Category D/X. First trimester: Exposure associated with minor malformations (cardiac defects, limb reduction) in some studies, but absolute risk low. Second/third trimester: Androgenic effects (. DELESTROGEN is classified as Category C. Delestrogen (estradiol valerate) is contraindicated in pregnancy. First trimester: associated with increased risk of congenital anomalies including cardiovascular and limb defects.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Ethinyl estradiol is primarily metabolized via CYP3A4; also undergoes sulfation and glucuronidation. Levonorgestrel is metabolized by reduction and conjugation, primarily via CYP3A4.
Estradiol is metabolized primarily in the liver via phase I hydroxylation by CYP3A4 and CYP1A2, followed by conjugation (glucuronidation and sulfation) to inactive metabolites (e.g., estrone, estriol, conjugates). Enterohepatic recirculation occurs.
Levonorgestrel and ethinyl estradiol are primarily eliminated via renal excretion (40-68% as metabolites) and fecal excretion (20-45%). Less than 1% is excreted unchanged.
Renal (primarily as glucuronide and sulfate conjugates, ~50-80%), fecal (~10-20%)
Levonorgestrel: 97-99% bound to sex hormone-binding globulin (SHBG) and albumin. Ethinyl estradiol: 95-97% bound to albumin. Induces SHBG synthesis, increasing its own binding capacity.
~98-99% bound primarily to sex hormone-binding globulin (SHBG) and albumin
Levonorgestrel: Vd ~1.4 L/kg (range 0.6-2.5 L/kg). Ethinyl estradiol: Vd ~2.4-4.3 L/kg. Indicates extensive tissue distribution and binding to sex hormone receptors.
Approximately 1-2 L/kg; indicates widespread distribution into tissues, including fat and reproductive organs
Oral bioavailability: levonorgestrel ~100% (due to high oral absorption and minimal first-pass metabolism); ethinyl estradiol ~40-55% (due to extensive first-pass metabolism and intestinal sulfation).
IM (estradiol valerate): 100% (prodrug rapidly hydrolyzed to estradiol); Oral estradiol: variable ~5-10% due to first-pass metabolism
Contraindicated in hepatocellular disease, acute or chronic liver disease, or history of liver tumors. For mild hepatic impairment (Child-Pugh A), use with caution and monitor liver function; dose adjustment not established. Moderate to severe impairment (Child-Pugh B or C) contraindicated.
Contraindicated in severe hepatic disease (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), use lowest effective dose and monitor liver function.
Approved for postmenarchal adolescents. Use same dosing as adults (tablet containing 0.1 mg levonorgestrel/0.02 mg ethinyl estradiol or 0.15 mg/0.03 mg, once daily). Weight-based dosing not required; adjust based on tolerability and efficacy.
Not approved for use in pediatric patients; safety and efficacy not established.
Not indicated for use in postmenopausal women; no specific dosing guidelines. Use only in nonmenopausal elderly women if benefits outweigh risks, with monitoring for cardiovascular and thromboembolic events.
Use lowest effective dose due to increased risk of thromboembolic events, cardiovascular disorders, and malignancy. Not recommended for prevention of dementia.
Estrogens should not be used to prevent cardiovascular disease or dementia. Increased risk of endometrial cancer, stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction. Breast cancer risk may be increased with combined estrogen-progestin therapy. Use lowest effective dose for shortest duration.
Cardiovascular disorders (stroke, DVT, PE, MI), malignancy (endometrial, breast, ovarian), dementia, gallbladder disease, hypercalcemia, visual abnormalities, fluid retention, hereditary angioedema, hypertriglyceridemia, hypothyroidism, exacerbation of asthma, diabetes, epilepsy, migraine, porphyria, SLE, hepatic hemangiomas, and severe hepatic impairment.
Undiagnosed abnormal genital bleeding, known/suspected breast cancer (except for appropriately selected cases), known/suspected estrogen-dependent neoplasia, active DVT/PE or history of these conditions, active arterial thromboembolic disease (e.g., stroke, MI), known thrombophilic disorders (e.g., protein C, S, or antithrombin deficiency), known or suspected pregnancy, liver dysfunction or disease, and hypersensitivity to any component.
Take with or without food; food may reduce nausea. Avoid grapefruit and grapefruit juice as they may increase estrogen levels and risk of side effects. No significant dietary restrictions otherwise.
Grapefruit juice may increase estradiol levels and should be avoided or limited. No other significant food interactions are known, but maintaining a healthy diet low in saturated fats is advised to reduce cardiovascular risk.
Levonorgestrel and ethinyl estradiol are excreted in breast milk in small amounts. M/P ratio for levonorgestrel approximately 1.1; ethinyl estradiol approximately 0.04. May reduce milk production and quality. Not recommended for use during breastfeeding, especially in early postpartum period.
Estrogen can decrease milk production and quality. Delestrogen is excreted in breast milk; M/P ratio is approximately 0.5-1.0. Use is contraindicated during breastfeeding due to potential adverse effects on the infant, including jaundice and transient breast enlargement.
No dose adjustment is applicable as use is contraindicated in pregnancy. Pharmacokinetic changes (increased volume of distribution, altered metabolism) would theoretically require adjustment if used, but no safety data exist.
Not applicable; Delestrogen is contraindicated in pregnancy. If exposure occurs, discontinue immediately. No dose adjustment is recommended as use should be avoided altogether.
Take one pill daily at the same time, without missing days.,If you miss a pill, follow package instructions; use backup contraception if needed.,Inform your provider if you smoke, especially if over 35; smoking increases risk of serious side effects.,Seek medical help immediately for signs of blood clot: leg pain/swelling, sudden chest pain, shortness of breath, or severe headache.,This medication does not protect against sexually transmitted infections; use condoms if protection needed.,If you experience severe vomiting or diarrhea, use additional contraception; absorption may be impaired.
This medication is given as an injection into a muscle, usually by a healthcare provider.,Report any signs of blood clots (chest pain, shortness of breath, leg swelling, sudden headache or vision changes) immediately.,Do not smoke while using this drug, as smoking increases risk of serious cardiovascular side effects.,Inform your doctor if you have a history of breast cancer, blood clots, liver disease, or unexplained vaginal bleeding.,Regular check-ups including blood pressure, mammograms, and pelvic exams are recommended.